Alliancebernstein L.P. Tcr2 Therapeutics Inc. Transaction History

Alliancebernstein L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.11 - $2.94 $46,842 - $65,268	-22,200 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$2.4 - $4.71 $12,240 - $24,021	-5,100 Reduced 18.68%	22,200 $61,000
Q2 2021 Jul 30, 2021	BUY	$16.41 - $24.71 $108,306 - $163,086	6,600 Added 31.88%	27,300 $448,000
Q1 2021 May 06, 2021	SELL	$20.38 - $34.07 $69,292 - $115,838	-3,400 Reduced 14.11%	20,700 $457,000
Q4 2020 Feb 08, 2021	BUY	$19.0 - $32.63 $248,900 - $427,453	13,100 Added 119.09%	24,100 $745,000
Q3 2020 Nov 12, 2020	SELL	$13.1 - $20.69 $66,810 - $105,519	-5,100 Reduced 31.68%	11,000 $224,000
Q2 2020 Aug 13, 2020	BUY	$6.51 - $16.85 $104,811 - $271,285	16,100 New	16,100 $247,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

Stay updated on Alliancebernstein L.P. with notifications on news.